Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome
I. Determine the induction of durable remission in patients with life-threatening systemic lupus erythematosus or antiphospholipid antibody syndrome treated with cyclophosphamide.
II. Determine the toxicity of this drug in these patients.
Systemic Lupus Erythematosus
Antiphospholipid Antibody Syndrome
|Study Design:||Allocation: Non-Randomized
Primary Purpose: Treatment
|Study Start Date:||April 1997|
Patients receive cyclophosphamide IV on days 1-4 and filgrastim (G-CSF) beginning on day 10 and continuing until blood counts recover.
Patients are followed monthly for 6 months, and then every 3 months thereafter.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00010400
|United States, Maryland|
|Johns Hopkins Oncology Center|
|Baltimore, Maryland, United States, 21231|
|Johns Hopkins University School of Medicine|
|Baltimore, Maryland, United States, 21205|
|Study Chair:||Robert A. Brodsky||Johns Hopkins University|